Merle, Philippe

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 7,470

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,789

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Cheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,743

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,106

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 535

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 343

Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma

Merle, P., de la Monte, S., Kim, M., Herrmann, M., Tanaka, S., Von Dem Bussche, A., Kew, M. C., Trepo, C., & Wands, J. R. (2004) · Gastroenterology

Wnt/β-catenin signaling in development and cancerHepatocellular Carcinoma Treatment and Prognosis

Cited by 249

Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma

Bengochea, A., de Souza, M. M., Lefrançois, L., Le Roux, E., Galy, O., Chemin, I., Kim, M., Wands, J. R., Trepo, C., Hainaut, P., et al. (2008) · British Journal of Cancer

Wnt/β-catenin signaling in development and cancerLiver physiology and pathology

Cited by 215

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

Abou-Alfa, G. K., Puig, O., Daniele, B., Kudo, M., Merle, P., Park, J.-W., Ross, P., Peron, J.-M., Ebert, O., Chan, S., et al. (2016) · Journal of Hepatology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 137

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Yau, T., Kaseb, A., Cheng, A.-L., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., et al. (2024) · The Lancet Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 97